News

Hold Abbott India Ltd For Target Rs.20315 - ICICI Direct Numbers miss despite decent growth in power brands…   About the stock: Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women’s health, GI, metabolic, pain, CNS among others. * Some top brands- Thyronorm, Udiliv, Duphalac, Duphaston, Cremafin Plus and Veritn have been the growth drivers besides new launches * Abbott has 140+ brands in segments of women’s health, gastroente...
Hold Abbott India Ltd For Target Rs.20315 - ICICI Direct
Hold Abbott India Ltd For Target Rs.20315 - ICICI Direct
Source: ICICI Direct
8/06/2023 2:01:53 PM
Abbott`s India arm posts 9.5% rise in fourth-quarter profit Abbott India Ltd reported a 9.5% jump in fourth-quarter profit on Friday, helped by strong sales in its mainstay pharmaceuticals segment. Profit for the company, which makes ibuprofen pain-reliever under the brand name Brufen, rose to 2.31 billion rupees ($28.3 million) in the three months ended March 31, from 2.11 billion rupees a year ago, the company said in an exchange filing. For further results highlights, click WHY IT MATTERS Abbot India, for which pharmaceutical is the sol...
Abbott`s India arm posts 9.5% rise in fourth-quarter profit
Abbott`s India arm posts 9.5% rise in fourth-quarter profit
Source: Reuters
19/05/2023 5:27:16 PM
Pfizer`s India unit posts 3% rise in Q4 profit Pfizer Ltd, the Indian unit of U.S. pharmaceutical group Pfizer Inc, on Monday reported a 3.1% rise in fourth-quarter profit, helped by lower raw material expenses. Net profit for the quarter ended March 31 rose to 1.30 billion rupees ($15.90 million) from 1.26 billion rupees a year ago, while revenue rose 4.2%. Pfizer also declared a final dividend of 35 rupees per share and a special dividend of 5 rupees per share. For further earnings highlights, click: WHY IT MATTERS Pfizer...
Pfizer`s India unit posts 3% rise in Q4 profit
Pfizer`s India unit posts 3% rise in Q4 profit
Source: Reuters
16/05/2023 9:04:29 AM
Hold Abbott India Ltd For Target Rs.21140 - ICICI Direct Weak poultry performance continues to weigh on numbers About the stock: Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women’s health, GI, metabolic, pain, CNS among othe * The company’s top five brands - (Mixtard, Thyronorm, Novomix, Udiliv and Duphaston) together posted revenue CAGR of ~6.6% MAT, March 2019-22 * Abbott has 140+ brands in segments of women’s health, gastroenterology,...
Hold Abbott India Ltd For Target Rs.21140 - ICICI Direct
Hold Abbott India Ltd For Target Rs.21140 - ICICI Direct
Source: ICICI Direct
17/08/2022 12:55:09 PM
Add Abbott India Ltd For Target Rs.18631 - ICICI Securities Strong quarter, high dividend Abbott India Limited’s (AIL) Q4FY22 performance was above our estimates across all fronts. Revenue grew 14.6% YoY to Rs12.6bn (I-sec: Rs11.6bn). EBITDA margin expanded 460bps YoY at 23.4% led by higher gross margin and lower expenses. Adjusted PAT grew 38.7% YoY to Rs2.1bn (I-Sec: Rs1.8bn). Growth during the quarter was led by traction in key products. Declining covid cases have paved the way for normalised environment; however, near-term growth could be...
Add Abbott India Ltd For Target Rs.18631 - ICICI Securities
Add Abbott India Ltd For Target Rs.18631 - ICICI Securities
Source: ICICI Securities Ltd
20/05/2022 12:12:56 PM
Abbott India rises on reporting 39% rise in Q4 net profit Abbott India is currently trading at Rs. 17701.00, up by 65.30 points or 0.37% from its previous closing of Rs. 17635.70 on the BSE. The scrip opened at Rs. 17543.00 and has touched a high and low of Rs. 17949.00 and Rs. 17450.10 respectively. So far 348 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 23902.30 on 05-Oct-2021 and a 52 week low of Rs. 15525.00 on 07-Feb-2022. Last one week high and low of the scr...
Abbott India rises on reporting 39% rise in Q4 net profit
Abbott India rises on reporting 39% rise in Q4 net profit
Source: Accord Fintech
18/05/2022 2:31:13 PM
Add Abbott India Ltd For Target Rs.19,156 - ICICI Securities In-line revenues; beat on margins Abbott India Limited’s (AIL) Q3FY22 performance was above our estimates on profitability front due to better-than-expected margins, while revenues (up 11.8% YoY to Rs12.2bn) were almost coincided with our estimate of Rs12.1bn. EBITDA margin was flat YoY at 22.0% though it was better than our estimate of 21.0%. Adj. PAT grew 12.5% YoY to Rs2bn (I-Sec: Rs1.8bn). Growth during the quarter was led by traction in key products and low base. We believe incr...
Add Abbott India Ltd For Target Rs.19,156 - ICICI Securities
Add Abbott India Ltd For Target Rs.19,156 - ICICI Securities
Source: ICICI Securities Ltd
3/03/2022 3:34:12 PM
Buy Abbott India Ltd : Decent quarter with sustained margins - ICICI Direct Buy Abbott India Ltd For Target Rs.20360 Decent quarter with sustained margins… About the stock: Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women’s health, GI, metabolic, pain, CNS among others. * The company’s top five brands - (Duphaston– gynaecological, Thyronorm– thyroid, Udiliv, Duphalac– both GI and Vertin- CNS) together posted revenue CAGR of ~13% in Marc...
Buy Abbott India Ltd : Decent quarter with sustained margins - ICICI Direct
Buy Abbott India Ltd : Decent quarter with sustained margins - ICICI Direct
Source: ICICI Direct
29/09/2021 9:29:40 AM
Buy Abbott India Ltd For Target Rs.18,621 - ICICI Securities In-line performance, growth to continue Abbott India Limited’s (AIL) Q1FY22 performance was in-line with our estimates with revenue growing 14.4% YoY to Rs12.2bn (I-Sec: Rs12.2bn). EBITDA margin improved 300bps QoQ to 21.8% (I-Sec: 20.0%) and adj. PAT grew 8.5% YoY to Rs2.0bn (I-Sec: Rs1.9bn). The growth during the quarter was led by traction in key products. While COVID-19 cases have been declining easing near term pressures, another wave could dent growth. We remain positive on ...
Buy Abbott India Ltd For Target Rs.18,621 - ICICI Securities
Buy Abbott India Ltd For Target Rs.18,621 - ICICI Securities
Source: ICICI Securities
28/09/2021 11:42:55 AM
Book Profit - Buy Abbott India Ltd For Target Rs. 18,929 - Sushil Finance We had coverage on Abbott India Ltd with a BUY rating on stock. Since our initiating report, the stock has posted a high of Rs.19,235 today and has achieved our target price of Rs.18,929.   With the recent run-up in the share price, our Target Price for the stock is achieved; hence, we are now changing our rating on the stock to Neutral and recommend our investors to book profits at the current price.   To Read Complete Report & Disclaimer Click Here   ...
Book Profit - Buy Abbott India Ltd For Target Rs. 18,929 - Sushil Finance
Book Profit - Buy Abbott India Ltd For Target Rs. 18,929 - Sushil Finance
Source: Sushil Finance
4/08/2021 1:27:02 PM
Buy Abbott India Ltd For Target Rs.18,497 - ICICI Securities Revenue growth starts recovering Abbott India Limited’s (AIL) Q4FY21 performance was better than our estimates with revenue growing 14.0% YoY to Rs10.9bn (I-Sec: Rs10.2bn). EBITDA margin improved 440bps YoY to 18.8% (I-Sec: 18.4%) and adj. PAT grew 37.4% YoY to Rs1.5bn (I-Sec: Rs1.5bn). The strong performance was due to traction in key products with fall in COVID-19 cases. Near term pressures continue with rising cases but expect recovery with ongoing vaccination. We remain positive ...
Buy Abbott India Ltd For Target Rs.18,497 - ICICI Securities
Buy Abbott India Ltd For Target Rs.18,497 - ICICI Securities
Source: ICICI Securities Ltd
11/06/2021 10:57:20 AM
Buy Abbott India Ltd For Target Rs. 19235 - ICICI Direct Sales recovery in the offing... While Q4FY21 results are not strictly comparable on a YoY basis due to pandemic related challenges in the base year, FY21 revenues grew 5.3% YoY to | 4310 crore likely moderated by the decline in 'Duphaston' (gynaecology) sales alongside demand slowdown in some other therapies amid the pandemic. EBITDA margins expanded 290 bps YoY to 21.4% with an overall better operational performance. EBITDA for the fiscal grew 21.8% YoY to | 922 crore. PAT was up ...
Buy Abbott India Ltd For Target Rs. 19235 - ICICI Direct
Buy Abbott India Ltd For Target Rs. 19235 - ICICI Direct
Source: ICICI Direct
10/06/2021 10:58:08 AM
Buy Abbott India Ltd For Target Rs.18,660 - Sushil Finance Abbott India Ltd. recently announced its performance for the quarter ended December 31, 2020. Following are the key highlights. Highlights from the Quarter (Q3 FY21) During Q3 FY21, the top-line grew by 1.6% YoY at Rs.1,095 cr and up by 3.8% as compared to Rs.1,055 cr on qoq basis. Gross margins improved by 80 bps yoy to 45.3% to Rs.495.7 cr in this quarter due to better product mix. Employee cost also remained flat YoY supporting margins. Rise in SG&A expenses neutralized the gros...
Buy Abbott India Ltd For Target Rs.18,660 - Sushil Finance
Buy Abbott India Ltd For Target Rs.18,660 - Sushil Finance
Source: Sushil Finance Ltd
26/03/2021 10:17:10 AM
Buy Abbott India Ltd For Target Rs.18,915 - ICICI Securities Weak performance; margins stable Abbott India Limited’s (AIL) Q3FY21 performance was muted and lower than our estimates. Revenue grew 1.6% YoY to Rs10.9bn (I-Sec: Rs11.5bn), EBITDA margin remained flat at 22.1% (I-Sec: 22.7%) and adj. PAT declined 5.1% YoY to Rs1.8bn (I-Sec: Rs2.0bn). The muted performance was due to slowdown in key products due to the challenging environment. Near term pressures continue but recovery is on the cards with easing of lockdown. We remain positive on th...
Buy Abbott India Ltd For Target Rs.18,915 - ICICI Securities
Buy Abbott India Ltd For Target Rs.18,915 - ICICI Securities
Source: ICICI Securities Ltd
10/03/2021 10:11:44 AM